Home Industries Market Insights About Us Publisher Contact us

Open Angle Glaucoma Market Growth, Trends and Forecast to 2028 – Global Analysis By Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, and Others), By End User (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers and Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others), and By Geography

Categories: Life Science   |   Formate :

MARKET DEFINITION

The term "glaucoma" refers to a group of illnesses in which elevated intraocular pressure negatively affects the optic nerve and, as a result, the visual field. However, not all cases of glaucoma are linked to elevated intraocular pressure; a subset known as normal pressure glaucoma has similar optic nerve impairment and visual field deterioration. Intraocular pressure (IOP) is a significant risk factor for open-angle glaucoma (OAG), a chronic, progressive, and irreversible multifactorial optic neuropathy that is characterized by an open angle of the anterior chamber, typical changes to the optic nerve head, progressive loss of peripheral vision (typical visual field changes), followed by central visual field loss (blindness).

MARKET DYNAMICS

The geriatric population is predicted to increase the patient population globally, which will drive the global angiomyolipoma market over the forecast period. The lack of skilled staff who are unable to treat patients with proper treatments may limit the growth of the global open angle glaucoma market over the forecast period. The increase in the number of open angle glaucoma therapies given through retail pharmacies, as well as the increase in the number of retail pharmacies in developed nations, creates prospects for market expansion. In addition, customers prefer retail pharmacies for drug purchases since they are more convenient.

REPORT SCOPE

The report titled “Global Open Angle Glaucoma Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Open Angle Glaucoma market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Open Angle Glaucoma market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Open Angle Glaucoma Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

GEOGRAPHICAL OVERVIEW

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

MARKET SEGMENTATION

The Global Open Angle Glaucoma Market is segmented based on drug class, end user, distribution channel, and region. Based on drug class, the market has been segmented into Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, and Others. Based on end user, the market has been segmented into Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers and Others, whereas, the distribution channel segmentation includes Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others.

COMPETITION LANDSCAPE

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Open Angle Glaucoma market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Open Angle Glaucoma market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Open Angle Glaucoma market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Open Angle Glaucoma industry in the past three years.

Key players in the Global Open Angle Glaucoma Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

  • Aerie Pharmaceuticals, Inc.
  • Bausch Health
  • Merck & Co. Inc.
  • Fera Pharmaceuticals
  • EyePoint Pharmaceuticals,Inc
  • Amorphex Therapeutics Holdings, Inc
  • Kubota Vision Inc
  • Alcon
  • Astellas Pharma Inc.
  • Bayer AG
  • Novartis AG
  • Carl Zeiss Meditec AG
  • Nidek Co Ltd
  • AqueSys
  • Iridex Corporation

COVID-19 IMPACT ANALYSIS ON GLOBAL OPEN ANGLE GLAUCOMA MARKET

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

Report Attribute/Metric

Details

Market Size

In USD Million

CAGR

In % (2022-2028)

Base Year

2021

Forecast Period

2022 – 2028

Historical Data

2017 to 2021

Forecast Unit

Value (US$ Mn)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors and Trends

Geographies Covered

North America, Europe, Asia-Pacific, South America, and Middle East & Africa

Key Players Analyzed

Aerie Pharmaceuticals, Inc., Bausch Health, Merck & Co. Inc., Fera Pharmaceuticals, EyePoint Pharmaceuticals,Inc, Amorphex Therapeutics Holdings, Inc, Kubota Vision Inc, Alcon, Astellas Pharma Inc., Bayer AG, Novartis AG, Carl Zeiss Meditec AG, Nidek Co Ltd, AqueSys and Iridex Corporation

Customization & Pricing

Available on Request (10% Customization is Free)

 

RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED

  1. What is the current size of the global Open Angle Glaucoma market?
  2. What will be the growth rate of the market over the forecast period?
  3. Who are the key manufacturers/vendors in the Open Angle Glaucoma market space?
  4. What are the major market opportunities and market risks faced by the market?
  5. What is the impact of COVID-19 on the market?
  6. What are the revenue, sales, and price analysis of the top manufacturers in this market?
  7. What are the key outcomes of Porter's five forces model?
  8. Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:

  • The report offers comprehensive data on the Open Angle Glaucoma market elaborating on the current state and future growth prospects both globally and regionally
  • It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth
  • The report offers deep-dive insights into each market segment and critical factors responsible for its growth
  • The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position
  • The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions
  • Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope
  • The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

 


 
Chapter 1. Executive Summary
1.1. Market Outlook
1.2. Market Segment Outlook
1.3. Geography Outlook
1.4. Absolute $ Opportunity
 
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Scope, Definition, and Assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary Data Mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
 
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key Trends
3.2.1. Drug Class Trends
3.2.2. End User Trends
3.2.3. Distribution Channel Trends
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Impact Analysis of Market Drivers
3.3.2. Market Restraints
3.3.2.1. Impact Analysis of Market Restraints
3.3.3. Market Opportunities
3.3.3.1. Impact Analysis of Market Opportunities
3.3.4. Market Challenges
3.3.4.1. Impact Analysis of Market Challenges
3.4. Porter’s Five Forces’ Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrant
3.4.4. Threat of Substitutes
3.4.5. Competitive Rivalry
3.5. Value Chain Analysis: Global Open Angle Glaucoma Market
3.6. COVID-19 Impact Assessment in Open Angle Glaucoma Market
3.6.1. Impact Assessment on Global Open Angle Glaucoma Market
3.6.2. Market Trends and Opportunities in the Covid-19 Landscape
 
Chapter 4. Global Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
4.1. Global Open Angle Glaucoma Market Share, By Drug Class, 2017 - 2028 (USD Million)
4.1.1. Beta Blockers
4.1.2. Prostaglandins
4.1.3. Alpha Adrenergic Agonist
4.1.4. Carbonic Anhydrase Inhibitors
4.1.5. Combination Drugs
4.1.6. Others

 
Chapter 5. Global Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
5.1. Global Open Angle Glaucoma Market Share, By End User, 2017 - 2028 (USD Million)
5.1.1. Hospitals
5.1.2. Homecare
5.1.3. Specialty Clinics
5.1.4. Ambulatory Surgical Centers
5.1.5. Others
 
Chapter 6. Global Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
6.1. Global Open Angle Glaucoma Market Share, By Distribution Channel, 2017 - 2028 (USD Million)
6.1.1. Hospital Pharmacy
6.1.2. Online Pharmacy
6.1.3. Retail Pharmacy
6.1.4. Others
 
Chapter 7. Global Open Angle Glaucoma Market Overview, By Geography, 2017 - 2028 (USD Million)
7.1. Global Open Angle Glaucoma Market Share, By Geography, 2017 - 2028 (USD Million)
7.1.1. Market Size and Projections, by Countries, 2017 - 2028 (USD Million)
7.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)
 
Chapter 8. North America Open Angle Glaucoma Market Overview, By Countries, 2017 - 2028 (USD Million)
8.1. North America Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
8.1.1. Market size and projections, 2017 - 2028 (USD Million)
8.1.2. North America Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.1.3. North America Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
8.1.4. North America Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2. North America Open Angle Glaucoma Market Overview, By Countries, 2017 - 2028 (USD Million)
8.2.1. U.S. Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
8.2.1.1. U.S. Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.1.2. U.S. Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
8.2.1.3. U.S. Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2.2. Canada Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
8.2.2.1. Canada Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.2.2. Canada Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
8.2.2.3. Canada Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2.3. Mexico Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
8.2.3.1. Mexico Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.3.2. Mexico Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
8.2.3.3. Mexico Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 9. Europe Open Angle Glaucoma Market Overview, By Countries, 2017 - 2028 (USD Million)
9.1. Europe Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
9.1.1. Market size and projections, 2017 - 2028 (USD Million)
9.1.2. Europe Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.1.3. Europe Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
9.1.4. Europe Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2. Europe Open Angle Glaucoma Market Overview, By Countries, 2017 - 2028 (USD Million)
9.2.1. Germany Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
9.2.1.1. Germany Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.1.2. Germany Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.1.3. Germany Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.2. France Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
9.2.2.1. France Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.2.2. France Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.2.3. France Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.3. UK Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
9.2.3.1. UK Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.3.2. UK Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.3.3. UK Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.4. Italy Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
9.2.4.1. Italy Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.4.2. Italy Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.4.3. Italy Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.5. Spain Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
9.2.5.1. Spain Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.5.2. Spain Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.5.3. Spain Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.6. NORDIC Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
9.2.6.1. NORDIC Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.6.2. NORDIC Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.6.3. NORDIC Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.7. Russia and CIS Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
9.2.7.1. Russia and CIS Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.7.2. Russia and CIS Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.7.3. Russia and CIS Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.8. Rest of Europe Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
9.2.8.1. Rest of Europe Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.8.2. Rest of Europe Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.8.3. Rest of Europe Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 10. Asia Pacific Open Angle Glaucoma Market Overview, By Countries, 2017 - 2028 (USD Million)
10.1. Asia Pacific Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
10.1.1. Market size and projections, 2017 - 2028 (USD Million)
10.1.2. Asia Pacific Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.1.3. Asia Pacific Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
10.1.4. Asia Pacific Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2. Asia Pacific Open Angle Glaucoma Market Overview, By Countries, 2017 - 2028 (USD Million)
10.2.1. India Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
10.2.1.1. India Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.1.2. India Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.1.3. India Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.2. China Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
10.2.2.1. China Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.2.2. China Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.2.3. China Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.3. Japan Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
10.2.3.1. Japan Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.3.2. Japan Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.3.3. Japan Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.4. ASEAN Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
10.2.4.1. ASEAN Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.4.2. ASEAN Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.4.3. ASEAN Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.5. South Korea Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
10.2.5.1. South Korea Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.5.2. South Korea Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.5.3. South Korea Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.6. Australia Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
10.2.6.1. Australia Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.6.2. Australia Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.6.3. Australia Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.7. Rest of Asia Pacific Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
10.2.7.1. Rest of Asia Pacific Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.7.2. Rest of Asia Pacific Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.7.3. Rest of Asia Pacific Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 11. South America Open Angle Glaucoma Market Overview, By Countries, 2017 - 2028 (USD Million)
11.1. South America Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
11.1.1. Market size and projections, 2017 - 2028 (USD Million)
11.1.2. South America Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.1.3. South America Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
11.1.4. South America Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2. South America Open Angle Glaucoma Market Overview, By Countries, 2017 - 2028 (USD Million)
11.2.1. Brazil Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
11.2.1.1. Brazil Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.1.2. Brazil Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.1.3. Brazil Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.2. Argentina Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
11.2.2.1. Argentina Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.2.2. Argentina Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.2.3. Argentina Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.3. Rest of South America Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
11.2.3.1. Rest of South America Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.3.2. Rest of South America Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.3.3. Rest of South America Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 12. Middle East & Africa Open Angle Glaucoma Market Overview, By Countries, 2017 - 2028 (USD Million)
12.1. Middle East & Africa Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
12.1.1. Market size and projections, 2017 - 2028 (USD Million)
12.1.2. Middle East & Africa Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.1.3. Middle East & Africa Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
12.1.4. Middle East & Africa Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2. Middle East & Africa Open Angle Glaucoma Market Overview, By Countries, 2017 - 2028 (USD Million)
12.2.1. GCC Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
12.2.1.1. GCC Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.1.2. GCC Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.1.3. GCC Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2.2. South Africa Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
12.2.2.1. South Africa Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.2.2. South Africa Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.2.3. South Africa Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2.3. Rest of Middle East & Africa Open Angle Glaucoma Market Overview, 2017 - 2028 (USD Million)
12.2.3.1. Rest of Middle East & Africa Open Angle Glaucoma Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.3.2. Rest of Middle East & Africa Open Angle Glaucoma Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.3.3. Rest of Middle East & Africa Open Angle Glaucoma Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 13. Competitive Landscape
13.1. Competitive Environment, 2021
13.2. Strategic Framework
13.2.1. Partnership/Collaborations/Agreement
13.2.2. Expansion
13.2.3. Mergers & Acquisitions
13.2.4. New Product Development
 
Chapter 14. Key Vendor Analysis
14.1. Aerie Pharmaceuticals, Inc.
14.1.1. Business Overview
14.1.2. Product Benchmarking
14.1.3. Financial Data
14.1.4. Strategic Overview
14.1.5. Key Developments
14.1.6. SWOT Analysis
14.2. Bausch Health
14.2.1. Business Overview
14.2.2. Product Benchmarking
14.2.3. Financial Data
14.2.4. Strategic Overview
14.2.5. Key Developments
14.2.6. SWOT Analysis
14.3. Merck & Co. Inc.
14.3.1. Business Overview
14.3.2. Product Benchmarking
14.3.3. Financial Data
14.3.4. Strategic Overview
14.3.5. Key Developments
14.3.6. SWOT Analysis
14.4. Fera Pharmaceuticals
14.4.1. Business Overview
14.4.2. Product Benchmarking
14.4.3. Financial Data
14.4.4. Strategic Overview
14.4.5. Key Developments
14.4.6. SWOT Analysis
14.5. EyePoint Pharmaceuticals,Inc
14.5.1. Business Overview
14.5.2. Product Benchmarking
14.5.3. Financial Data
14.5.4. Strategic Overview
14.5.5. Key Developments
14.5.6. SWOT Analysis
14.6. Amorphex Therapeutics Holdings, Inc
14.6.1. Business Overview
14.6.2. Product Benchmarking
14.6.3. Financial Data
14.6.4. Strategic Overview
14.6.5. Key Developments
14.6.6. SWOT Analysis
14.7. Kubota Vision Inc
14.7.1. Business Overview
14.7.2. Product Benchmarking
14.7.3. Financial Data
14.7.4. Strategic Overview
14.7.5. Key Developments
14.7.6. SWOT Analysis
14.8. Alcon
14.8.1. Business Overview
14.8.2. Product Benchmarking
14.8.3. Financial Data
14.8.4. Strategic Overview
14.8.5. Key Developments
14.8.6. SWOT Analysis
14.9. Astellas Pharma Inc.
14.9.1. Business Overview
14.9.2. Product Benchmarking
14.9.3. Financial Data
14.9.4. Strategic Overview
14.9.5. Key Developments
14.9.6. SWOT Analysis

14.10. Bayer AG
14.10.1. Business Overview
14.10.2. Product Benchmarking
14.10.3. Financial Data
14.10.4. Strategic Overview
14.10.5. Key Developments
14.10.6. SWOT Analysis
14.11. Novartis AG
14.11.1. Business Overview
14.11.2. Product Benchmarking
14.11.3. Financial Data
14.11.4. Strategic Overview
14.11.5. Key Developments
14.11.6. SWOT Analysis
14.12. Carl Zeiss Meditec AG
14.12.1. Business Overview
14.12.2. Product Benchmarking
14.12.3. Financial Data
14.12.4. Strategic Overview
14.12.5. Key Developments
14.12.6. SWOT Analysis
14.13. Nidek Co Ltd
14.13.1. Business Overview
14.13.2. Product Benchmarking
14.13.3. Financial Data
14.13.4. Strategic Overview
14.13.5. Key Developments
14.13.6. SWOT Analysis
14.14. AqueSys
14.14.1. Business Overview
14.14.2. Product Benchmarking
14.14.3. Financial Data
14.14.4. Strategic Overview
14.14.5. Key Developments
14.14.6. SWOT Analysis
14.15. Iridex Corporation
14.15.1. Business Overview
14.15.2. Product Benchmarking
14.15.3. Financial Data
14.15.4. Strategic Overview
14.15.5. Key Developments
14.15.6. SWOT Analysis
 
Chapter 15. Future Outlook of the Market

 

Request For Methodology

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any)

Request For List Of Tables

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any)

FAQ

Choose License Type

Single User

US$ 3500

Multi User

US$ 5250

Corporate User

US$ 7000

Personalize this Research

  • Market Size and Share from 2016 - 2027
  • Expected Market Growth Until 2027
  • COVID-19 Impact assessment on the market
  • Market Dynamics and Impact Analysis
  • Segment and region that will drive or lead the market growth and why
  • Industry activity comprising Mergers, Acquisitions, Expansion, etc.
  • Comprehensive Mapping of the Competitive Landscape
  • In-depth analysis of key sustainability strategies adopted by market players
  • Global and regional market trends – Current and Future
  • Value Chain Analysis
  • Porters Five Forces Analysis
  • Historical and Current Product Pricing
  • Country Cross-Segment Analysis
  • Company Profiling
  • Player Comparison Matrix

Life Science Clients

Open Angle Glaucoma Market Growth, Trends and Fore...

RD Code : HP22